AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages

AXL启动的pSTAT3旁分泌激活增强了肿瘤相关巨噬细胞的间质和血管生成支持特性

阅读:5
作者:Chia-Nung Hung ,Meizhen Chen ,Daniel T DeArmond ,Cheryl H-L Chiu ,Catherine A Limboy ,Xi Tan ,Meena Kusi ,Chih-Wei Chou ,Li-Ling Lin ,Zhao Zhang ,Chiou-Miin Wang ,Chun-Liang Chen ,Kohzoh Mitsuya ,Pawel A Osmulski ,Maria E Gaczynska ,Nameer B Kirma ,Ratna K Vadlamudi ,Don L Gibbons ,Steve Warner ,Andrew J Brenner ,Daruka Mahadevan ,Joel E Michalek ,Tim H-M Huang ,Josephine A Taverna

Abstract

Tumor-associated macrophages (TAMs) are integral to the development of complex tumor microenvironments (TMEs) and can execute disparate cellular programs in response to extracellular cues. However, upstream signaling processes underpinning this phenotypic plasticity remain to be elucidated. Here, we report that concordant AXL-STAT3 signaling in TAMs is triggered by lung cancer cells or cancer-associated fibroblasts in the cytokine milieu. This paracrine action drives TAM differentiation toward a tumor-promoting "M2-like" phenotype with upregulation of CD163 and putative mesenchymal markers, contributing to TAM heterogeneity and diverse cellular functions. One of the upregulated markers, CD44, mediated by AXL-IL-11-pSTAT3 signaling cascade, enhances macrophage ability to interact with endothelial cells and facilitate formation of primitive vascular networks. We also found that AXL-STAT3 inhibition can impede the recruitment of TAMs in a xenograft mouse model, thereby suppressing tumor growth. These findings suggest the potential application of AXL-STAT3-related markers to quantitatively assess metastatic potential and inform therapeutic strategies in lung cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。